Although their study population was not large enough to evaluate rare events such as RCC, the authors did cite a potential benefit of using mTOR inhibitors in routine immunosuppression protocols: minimization of the risk of post-transplant malignancy. The gene discussed is MTOR; the disease is renal cell carcinoma.